XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: July 10, 2025
First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT‑2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease
More >>
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>